ANZMTG - Australia and New Zealand Melanoma Trials Group Home | Login
ANZMTG - Australia and New Zealand Melanoma Trials Group
 

LOGIN



Please enter your username and password.


Username

Password


  
ANZMTG
 

ANZMTG 01.12 EAGLE FM Trial - Inguinal or Ilio-inguinal Lymphadenectomy for patients with metastatic melanoma to groin lymph nodes and no evidence of pelvic disease on PET/CT Scan - A randomised phase III trial

Spread of metastatic melanoma to the groin lymph nodes is a common event for patients with melanoma. In melanoma treatment centres around the world, management of patients with clear pelvic lymph node disease vary. This multi-centre, phase III, prospective, randomised clinical trial aims to assess the effectiveness and morbidity of Complete Inguinal Lymph Node Dissection versus Complete Ilio-ingional Lymph Node Dissection for patients with metastatic melanoma and negative pelvic staging on PET / CT scan.

Study Status: Open to recruitment
Clinical Trials Registry number: ACTRN12614000721606
ClinicalTrials.gov identifier: NCT02166788

Principal Investigator's details:

Prof Andrew Spillane

Melanoma Institute Australia 

Email: andrew.spillane@melanoma.org.au

 

ANZMTG coordinator details:

 

Email: anzmtg0112@melanoma.org.au

Phone: +61 2 9911 7352

Documents (PDF downloads):


Return to Previous Page